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Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target, EGFR tyrosine kinase
inhibitors (TKIs) have been used in lung cancer patients with EGFR mutations, which has been a major
breakthrough for lung cancer treatment.. The progression-free survival (PFS) of patients with EGFR mutations
treated with EGFR TKIs is significantly prolonged compared with that of patients who underwent standard
chemotherapy. However, all patients who initially respond to EGFR TKIs eventually develop acquired resistance
(AR). Many small molecule agents and monoclonal antibodies (McAb) targeting signaling pathways are potential
therapeutic
regimens for overcoming resistance, and various therapeutic strategies are used in clinical practice. Here we
review the novel agents and therapeutic strategies for overcoming AR to EGFR TKIs.
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Non-small cell lung cancer (NSCLC) accounts for
approximately 80% of all lung cancer cases [1]. The trad-
itional treatment for NSCLC is platinum-based chemo-
therapy, which inhibits normal and cancer cells, but it has
reached a therapeutic plateau [2]. In contrast, personalized
therapy has numerous advantages [3]. The ERBB family
includes EGFR/HER1, ERBB2/HER2, ERBB3/HER3 and
ERBB4/HER4. Somatic EGFR mutations result in con-
formational changes and the activation of downstream sig-
naling. Gefitinib and erlotinib are first-generation EGFR
TKIs that reversibly compete with the ATP-binding site in
the EGFR. Gefitinib/erlotinib (G/E) prolongs progression-
free survival (PFS) and improves quality of life compared
with standard chemotherapy, while almost all patients
develop AR to G/E in 9 to 11 months [4].
The mechanisms responsible for AR to G/E include
the following: first, secondary EGFR mutation, which is
predominantly T790M; second, activation of parallel sig-
naling pathways; third, activation of downstream signaling
pathways; fourth, phenotypic transformation, such as
epithelial to mesenchymal transition (EMT) and small cell
lung cancer (SCLC) transformation. We will discuss the* Correspondence: syylwu@live.cn
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stated.mechanisms of AR to G/E and corresponding novel tar-
geting agents (Figure 1). The potential therapeutic options
for patients with AR to EGFR TKIs are also reviewed.
New agents for overcoming AR
Secondary EGFR mutations
The most common type of AR is mutation in codon 790
(T790M) in EGFR exon 20, which accounts for 50 ~ 60%
of cases with AR to G/E [5]. EGFR T790M leads to a
higher affinity of ATP for EGFR, thus affecting G/E
binding [6]. Second generation EGFR TKIs e.g., BIBW
2992 (afatinib) and PF00299804 (dacomitinib), and third
generation EGFR TKIs e.g., CO-1686 and AZD9291 are
irreversible inhibitors that could overcome the AR caused
by T790M. Afatinib has been approved by the FDA.
Dacomitinib, CO-1686 and AZD9291 are currently being
tested in ongoing trials.
Afatinib
The safety and efficacy of afatinib have been characte-
rized in many clinical trials. The most classic trial is the
LUX-Lung program. This program evaluated the efficacy
of afatinib for first-line treatment and for patients who
have been treated with G/E. The efficacy of afatinib in
overcoming AR to G/E was confirmed in the LUX-Lung
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Figure 1 New agents for overcoming AR. This figure shows the parallel and downstream signaling pathways of the EGFR. The gray boxes depict
new agents available for treatment.
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chemotherapy were enrolled in LUX-Lung 1 [7], and
these patients were randomized to receive afatinib or
placebo. The primary endpoint, overall survival (OS), was
10.8 months in the afatinib group, while the outcome was
12.0 months in placebo group (HR = 1.077, P = 0.74).
However, PFS was significantly prolonged in the afatinib
group (3.3 vs. 1.1 months, HR = 0.38; p < 0.0001). More-
over, symptoms such as cough and dyspnea were signifi-
cantly improved in the afatinib group.
LUX-Lung 4 [8] also confirmed the efficacy of afatinib
in patients who progressed on G/E and chemotherapy.
In the 61 evaluable patients, partial response (PR) was
achieved in 4 patients, and the median PFS and OS was
4.4 and 19.0 months, respectively.
Afatinib was investigated in patients who failed
chemotherapy and G/E in LUX-Lung 5 [9]. The patients
were randomized into two groups after afatinib resist-
ance i.e., afatinib alone or afatinib combined with pacli-
taxol. In part A of the trial, 63% of the patients achieved
complete response (CR)/PR/stable disease (SD), and the
median PFS was 3.3 months. The results of part B are
pending.
Dacomitinib
In a phase II trial, dacomitinib was given to patients with
advanced NSCLC after chemotherapy (CT) and erlotinib
(E) failure. In 62 evaluable cases, 3 had a partial res-
ponse, and 35 had stable disease (SD) for more than 6
weeks. The side effects included diarrhea (86%), fatigue(40%), rash (45%), and stomatitis/mucosal inflammation,
which was mainly grade 1/2 and manageable [10]. One
patient with a T790M mutation caused by prior gefitinib
treatment achieved SD after exposure to dacomitinib in
the NCT00783328 trial [11]. Four patients who have
failed G/E achieved PR in a phase I trial (NCT00225121)
[12]. NCT01000025 is an ongoing phase III trial that
investigates the efficacy of dacomitinib in patients with
NSCLC who have failed chemotherapy and G/E.
CO-1686 and AZD9291
CO-1686 is a third-generation EGFR TKI, which may be
more effective in patients with T790M. NCT01526928 is
an ongoing phase I/II trial that has enrolled patients
who have failed prior chemotherapy and EGFR-targeted
therapy including erlotinib, gefitinib, neratinib, afatinib,
or dacomitinib. Three cases treated with CO-1686 de-
monstrated clinical benefit or tumor shrinkage, and the
tolerance was acceptable [13].
AZD9291 is a potent oral, irreversible inhibitor of the
EGFR with EGFR-TKI-sensitizing (EGFR+) and resis-
tance mutations (T790M). The AZD9291 IC50 for the
EGFR+/T790M H1975 cells is 15 nM. In a phase I open-
label multicenter study, AZD9291 was shown to have
mostly mild AEs, and no grade 3-4 SAEs were observed.
Moreover, 89 patients received at least one dose, and no
DLTs were observed. Good evidence for efficacy has
been observed at all doses studied thus far, including
9/18 patients with T790M who had confirmed or un-
confirmed partial responses [14].
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MET amplication/overexpression
The incidence of MET gene amplication or protein over-
expression is 5 ~ 22% in AR patients [15]. MET activates
ERBB3 and the PI3K/AKT pathway independent of EGFR
[16]. MetMAb [17] and ARQ197 (tivantinib) [18] are the
most prominent MET inhibitors, but they have not been
investigated for overcoming TKI resistance.
NCT01610336 and NCT01911507 are ongoing trials
that test the safety and efficacy of INC280 in NSCLC
patients with AR to G/E. INC280 and gefitinib are
simultaneously given to patients with MET-amplification
in the NCT01610336 trial. Patients with MET over-
expression are treated with INC280 and erlotinib in the
NCT01911507 trial. The results of these trials are not
yet available.
XL184 is a tyrosine kinase inhibitor of multiple recep-
tors, including VEGFR2, MET, and RET. NCT00596648
is a phase Ib/II trial evaluating the safety and efficacy of
XL184 with or without erlotinib in patients resistant to
EGFR TKIs, and its results are pending.
HGF overexpression
Approximately 60% patients with AR to G/E have HGF
overexpression [19]. The overexpression results in MET
phosphorylation and the activation of GAB1 and PI3K/
AKT [20]. BEZ235 is PI3K-mTOR inhibitor that has the
potential to overcome AR in vitro [21]. However, the
efficacy of BEZ235 has not been tested in vivo. Heat
shock protein 90 (HSP90) is a molecular chaperone for
several proteins, including EGFR and MET. 17-DMAG
is an HSP90 inhibitor that has efficacy for HGF-
triggered erlotinib resistance in cell lines and animal
models [22]. AUY922 is also an HSP90 inhibitor that is
currently being tested in the phase II trial NCT01259089.
This trial enrolled patients with AR to G/E. The ORR was
13%, and the two patients with a PR had an EGFR T790M
mutation [23].
Downstream signaling pathway activation
The downstream signaling pathways of EGFR include
the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR path-
ways. The former is associated with proliferation, and
the latter is related to survival. Mutations in EGFR result
in activation of the PI3K/AKT pathway and the survival
of tumor cells without affecting tumor cell proliferation.
The mutation of key genes in these two pathways leads
to G/E resistance.
PIK3CA mutation
PIK3CA mutations were detected in 5% of patients with
AR to G/E [24]. The most promising PI3K inhibitor is
BKM120, which is a pan-PI3K inhibitor. The antitu-
mor activation of gefitinib plus BKM120 was observedin patients with AR to G/E in the phase Ib trial
NCT01570296 [25]. A reduction in SUVmax (>25%)
was observed in 4/10 patients, and the median PFS
was 2.8 months. Given the favorable central nervous
system (CNS) penetration of BKM120, patients with
brain metastases were included, and two patients with
CNS penetration had a PFS of 2.8 and 10.7 months. How-
ever, molecular analysis revealed that no patient harbored
a PIK3CA mutation. NCT01487265 is an ongoing phase
I/II trial examines the efficacy of BKM120 combined with
erlotinib in patients with AR to erlotinib, and the results
of this trial are pending.
AKT
AKT mutations were not detected in patients with AR
to G/E [26], but AKT might be activated in tumors
resistant to G/E. MK2206 is one of the most potent
AKT inhibitors. Growth inhibition was greatly enhanced
with the combination of MK2206 and erlotinib in
TKI-sensitive and TKI-resistant NSCLC cell lines, and
MK-2206 restored erlotinib sensitivity in HGF-induced AR
cells [27]. There are two ongoing trials, NCT01294306 and
NCT01147211, which examine the efficacy of MK2206 in
NSCLC patients with AR to erlotinib and gefitinib, re-
spectively, but their results are unavailable.
mTOR
mTOR regulates cell growth and metabolism by con-
trolling several catabolic and anabolic processes. mTOR
inhibitors include temsirolimus, everolimus (RAD001),
Ku-0063794, and sirolimus.
Temsirolimus and everolimus could overcome HGF-
induced EGFR TKI AR in vitro [28]. Everolimus enhanced
the antitumor activation of gefitinib in sensitive and resist-
ant cell lines [29] but failed to meet the primary endpoint
in a phase II trial [30]. Ku-0063794 could effectively
inhibit gefitinib-resistant cells [31]. NCT00993499 is an
ongoing phase Ib trial in which the efficacy of the combin-
ation of afatinib and sirolimus is being tested in patients
with AR to gefitinib or erlotinib, and the results are
pending.
ERK2 amplification
ERK2 (MAPK1) amplification has been reported in 5%
of patients with AR to G/E [32]. AZD6244 and CI1040
could reverse resistance in cells with AR to gefitinib
[33]; however, there is no clinical trial that has evaluated
the efficacy of overcoming AR to AZD6244 and CI1040.
Strategies for overcoming AR
IMPRESS model
Some patients may have accelerated disease progression
after discontinuing G/E during washout periods. This
phenomenon is called disease flare, which was observed
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some clinicians suggest G/E continuation plus chemo-
therapy. There was a retrospective study demonstrating
that erlotinib continuation in addition to chemotherapy
significantly improved the respond rate (RR) compared
with chemotherapy alone after erlotinib failure [35].
IMPRESS is an ongoing phase III trial enrolling patients
with EGFR mutations who failed first-line gefitinib. The
patients are randomized to receive cisplatin and peme-
trexed plus gefitinib or placebo. The primary endpoint
of this study is PFS, and the results are pending.
ASPIRATION model
As EGFR TKIs greatly improve the PFS of patients with
EGFR positive mutations, the RECIST definition of
progression now appears to be challenged. Recently
Yang et al. reported a retrospective study that divided
patients with AR into three groups: dramatic progres-
sion, local progression and gradual progression. The
authors recommended chemotherapy for patients with
dramatic progression, the continuation of TKIs plus
local intervention for those with local progression and
the continuation of TKIs for those with gradual progres-
sion [36]. ASPIRATION is an ongoing phase II study
evaluating the continuation of erlotinib beyond RECIST
PD in selected patients who have slowed PD (>6 months
of partial response/stable disease), asymptomatic minimal
PD, or new, locally controlled brain metastases.
Switching to or combining with novel compounds
With the unveiling of the underlying mechanisms of AR,
novel small molecule inhibitors alone or in combination
will be effective in overcoming AR e.g., INC280 plus
gefitinib or erlotinib as mentioned above. Therefore, we
should recommend that patients receive rebiopsies after
progression on G/E to identify the underlying mecha-
nisms of AR. Based on the understanding of resistance
mechanisms, clinicians should encourage patients to
enter clinical trials.
Conclusion
EGFR TKIs are increasingly used in the clinic. The stan-
dard treatment for patients with AR to EGFR TKIs is
changing to chemotherapy at RECIST progression. How-
ever, this standard treatment is now being challenged due
to a growing number of effective novel compounds and
clinical trial strategies.
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